Myriad Genetics (MYGN) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free MYGN Stock Alerts $24.86 -0.15 (-0.60%) (As of 10:09 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17, 2024 | insidertrades.comPaul J. Diaz Sells 57,844 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) StockMay 17, 2024 | americanbankingnews.comPaul J. Diaz Sells 75,000 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) StockMay 16, 2024 | globenewswire.comNew Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate CancerMay 16, 2024 | insidertrades.comLee Nisley Newcomer Sells 6,200 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) StockMay 16, 2024 | finance.yahoo.comInsider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)May 16, 2024 | finance.yahoo.comInsider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)May 15, 2024 | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) PT Raised to $28.00 at Piper SandlerMay 13, 2024 | marketbeat.comPiper Sandler Boosts Myriad Genetics (NASDAQ:MYGN) Price Target to $28.00Piper Sandler raised their price objective on Myriad Genetics from $23.00 to $28.00 and gave the company a "neutral" rating in a report on Monday.May 12, 2024 | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) Upgraded to Outperform at SVB LeerinkMay 12, 2024 | marketbeat.comNatixis Advisors L.P. Increases Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)Natixis Advisors L.P. boosted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 44.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 190,278 shares of the company's stock after purchasinMay 11, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter ReportMay 11, 2024 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 9, 2024 | msn.comLeerink Partners Upgrades Myriad Genetics (MYGN)May 9, 2024 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Reaches New 1-Year High at $24.92Myriad Genetics (NASDAQ:MYGN) Hits New 1-Year High at $24.92May 9, 2024 | finance.yahoo.comMyriad Genetics First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | marketwatch.comMyriad Genetics Shares Rise 15% After 1Q Revenue Beats EstimatesMay 8, 2024 | finance.yahoo.comMyriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Shares Gap Up Following Strong EarningsMyriad Genetics (NASDAQ:MYGN) Shares Gap Up After Strong EarningsMay 8, 2024 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Lifted to "Outperform" at SVB LeerinkSVB Leerink raised Myriad Genetics from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $25.00 to $35.00 in a report on Wednesday.May 8, 2024 | finance.yahoo.comMyriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript Highlights: Strong Start with ...May 8, 2024 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings GuidanceMyriad Genetics (NASDAQ:MYGN) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.000-0.050 for the period, compared to the consensus estimate of 0.020. The company also issued revenue guidance of $820.0 millionillion-$840.0 millionillion, compared to the consensus estimate of $826.6 millionillion.May 7, 2024 | investorplace.comMYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | uk.finance.yahoo.comMyriad Genetics Reports Q1 2024 Earnings: Revenue Growth Surpasses Estimates Amidst ChallengesMay 7, 2024 | markets.businessinsider.comMyriad Genetics Inc. Q1 Loss Decreases, beats estimatesMay 7, 2024 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPSMyriad Genetics (NASDAQ:MYGN - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.09. Myriad Genetics had a negative net margin of 34.96% and a negative return on equity of 8.03%. The firm had revenue of $202.20 million for the quarter, compared to analyst estimates of $193.51 million. During the same period last year, the business earned ($0.28) EPS. Myriad Genetics's revenue for the quarter was up 11.6% compared to the same quarter last year.May 7, 2024 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Issues FY24 Earnings GuidanceMyriad Genetics (NASDAQ:MYGN) updated its FY24 earnings guidance. The company provided EPS guidance of $0.00 to $0.05 for the period, compared to the consensus estimate of $0.03.May 7, 2024 | msn.comMyriad Genetics GAAP EPS of -$0.29 beats by $0.01, revenue of $202.2M beats by $8.95MMay 7, 2024 | globenewswire.comMyriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDAMay 7, 2024 | finanznachrichten.deMyriad Genetics, Inc.: Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict BusinessMay 7, 2024 | globenewswire.comMyriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict BusinessMay 7, 2024 | finance.yahoo.comMyriad Genetics (NASDAQ:MYGN) shareholders have endured a 26% loss from investing in the stock five years agoMay 7, 2024 | markets.businessinsider.comMyriad Genetics earnings preview: what Wall Street is expectingMay 6, 2024 | seekingalpha.comMyriad Genetics Q1 2024 Earnings PreviewMay 2, 2024 | finance.yahoo.comYourBio Health Congratulates Myriad Genetics on One Million Sales of SneakPeek® Tests Enabled by YourBio's Virtually Painless TAP TechnologyMay 1, 2024 | marketbeat.comMyriad Genetics (MYGN) Scheduled to Post Quarterly Earnings on TuesdayMyriad Genetics (NASDAQ:MYGN) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports.April 30, 2024 | finance.yahoo.comMyriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024April 29, 2024 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Stock Price Up 6.6%Myriad Genetics (NASDAQ:MYGN) Shares Up 6.6%April 28, 2024 | msn.comAroa Biosurgery to target US$300 million trauma market with Myriad productsApril 27, 2024 | marketbeat.comLouisiana State Employees Retirement System Takes Position in Myriad Genetics, Inc. (NASDAQ:MYGN)Louisiana State Employees Retirement System bought a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 44,400 shares of the company's stock, valued at approximately $850,000. Louisiana SApril 17, 2024 | tmcnet.comNearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorApril 17, 2024 | finance.yahoo.comNearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorApril 17, 2024 | finance.yahoo.comNearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorApril 17, 2024 | globenewswire.comNearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorApril 17, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $3.55 Million Position in Myriad Genetics, Inc. (NASDAQ:MYGN)Mirae Asset Global Investments Co. Ltd. lowered its position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 55.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 185,483 shares of the company'sApril 16, 2024 | globenewswire.comNew Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal ScreenApril 15, 2024 | barrons.comMyriad Genetics Inc.April 11, 2024 | uk.investing.comMyriad Genetics psychotropic test 'GeneSight' linked to lower hospitalization in depression patientsApril 9, 2024 | globenewswire.comMyriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight TestingApril 6, 2024 | marketbeat.com108,377 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Bought by Kent Lake Capital LLCKent Lake Capital LLC bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 108,377 shares of the company's stock, valued aApril 6, 2024 | finance.yahoo.comNovavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound? Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Read this before you buy AI stocks (Ad)BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. MYGN Media Mentions By Week MYGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYGN News Sentiment▼0.180.43▲Average Medical News Sentiment MYGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYGN Articles This Week▼104▲MYGN Articles Average Week Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CLDX News NTLA News NEOG News QDEL News LNTH News PDCO News APGE News AGL News ASTH News RXRX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYGN) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market Insiders[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
